| Page 1230 | Kisaco Research
 

Jesse Stanley

CEO
Stanley Brothers

Since 2009, Jesse Stanley has been on a journey, with his seven brothers, to unleash the healing powers of botanical wellness, starting with the then little-known cannabinoid, CBD.

 

This endeavor led the brothers to search for the optimal genetics, ultimately discovering them in wild hemp that grew across middle America. These genetics would later become the basis of their hemp-based CBD products, named after a brave little girl, Charlotte Figi who struggled with catastrophic Epilepsy.

 

Jesse Stanley

CEO
Stanley Brothers

Jesse Stanley

CEO
Stanley Brothers

Since 2009, Jesse Stanley has been on a journey, with his seven brothers, to unleash the healing powers of botanical wellness, starting with the then little-known cannabinoid, CBD.

 

This endeavor led the brothers to search for the optimal genetics, ultimately discovering them in wild hemp that grew across middle America. These genetics would later become the basis of their hemp-based CBD products, named after a brave little girl, Charlotte Figi who struggled with catastrophic Epilepsy.

 

In 2013, the world was introduced to the Stanley Brothers' mission when CNN’s Dr. Sanjay Gupta featured Charlotte’s life-changing story, which ultimately became the tipping point for thousands of medical refugees to move to Colorado to acquire the Brothers’ tincture. Charlotte’s story challenged public perception, changed laws, ignited research, and accelerated the CBD industry both in the United States and across the world.

 

As the world took notice, the company rapidly expanded, and in 2018, Charlotte’s Web completed an IPO and with the 2020 acquisition of Abacus Health, Charlotte’s Web has now become the global leader in hemp-based CBD products.

 

Jesse Stanley continues to advance his brothers’ founding mission with upcoming projects from Stanley Brothers USA, channeling the beneficial uses of the whole cannabis plant with all cannabinoids, flavonoids, and terpenes working together in conjunction with other functional botanicals for targeted wellness outcomes. As CEO, he leads a brand centered on creating an even larger footprint for all cannabis users whose focus is on health, wellness, and balance to drive their daily lives.

 

Jacques Tortoroli

CEO
Charlotte’s Web

Jacques Tortoroli is the CEO of Charlotte’s Web, the market-leading pioneer of the CBD industry. He has served on the Charlotte’s Web Board of Directors since November 2019.

 

Prior to Charlotte’s Web, Mr. Tortoroli served as the President of Bacardi International Limited as well as Chief Financial Officer and Chief Administrative Officer in his six-year tenure at Bacardi Ltd, the world’s largest privately held spirits company, where he was responsible for the company’s finance, strategy, operations, e-commerce, data insights, and global supply chain.

 

Jacques Tortoroli

CEO
Charlotte’s Web

Jacques Tortoroli

CEO
Charlotte’s Web

Jacques Tortoroli is the CEO of Charlotte’s Web, the market-leading pioneer of the CBD industry. He has served on the Charlotte’s Web Board of Directors since November 2019.

 

Prior to Charlotte’s Web, Mr. Tortoroli served as the President of Bacardi International Limited as well as Chief Financial Officer and Chief Administrative Officer in his six-year tenure at Bacardi Ltd, the world’s largest privately held spirits company, where he was responsible for the company’s finance, strategy, operations, e-commerce, data insights, and global supply chain.

 

Mr. Tortoroli has provided global executive leadership for some the world’s top brands. He has led global finance, mergers & acquisitions, and strategic partnerships through various senior executive roles at Viacom Inc., Young & Rubicam Inc., PepsiCo Inc., and KPMG.

 

In October 2019, Mr. Tortoroli was named the Executive in Residence and Vice President of Institutional Advancement and Student Career Services at St. Thomas Aquinas College. Mr. Tortoroli is also Chair of the Board and Advisor to the Chief Executive Officer of Gameday Gateway, a certified Women’s Business Enterprise. Mr. Tortoroli holds a bachelor’s degree in Accounting from St. Francis College in Brooklyn, New York.‎

 

Rogier Rooswinkel

General Partner
Forbion

Rogier Rooswinkel

General Partner
Forbion

Rogier Rooswinkel

General Partner
Forbion
 

Sean Arlauckas

Director of Oncology
Be Biopharma

Sean Arlauckas

Director of Oncology
Be Biopharma

Sean Arlauckas

Director of Oncology
Be Biopharma
 

Camilla Fairbairn

Senior Scientist
bit.bio

Camilla Fairbairn

Senior Scientist
bit.bio

Camilla Fairbairn

Senior Scientist
bit.bio
 

Dr. Grzegorz Wesela-Bauman

Senior Counsel - Patents
GE Power

Dr. Grzegorz Wesela-Bauman

Senior Counsel - Patents
GE Power

Dr. Grzegorz Wesela-Bauman

Senior Counsel - Patents
GE Power
 

Daniel Larcombe-Young

PhD Student & Scientific Consultant
Leucid Bio

Daniel Larcombe-Young

PhD Student & Scientific Consultant
Leucid Bio

Daniel Larcombe-Young

PhD Student & Scientific Consultant
Leucid Bio
 

Dr. Stefan Horstmann

VP of PS Core - Patents and Scientific Services
Merck KGaA

Dr. Stefan Horstmann is VP of PS Core - Patents and Scientific Services at Merck KGaA.

Dr. Horstmann holds a PhD in Chemistry and is qualified as European and German Patent Attorney. Before becoming a VP of PS Core, he previously served as Head of the Patents B2B Department, and has also served as in-house patent attorney at Merck KGaA and Henkel KGaA and as an IT consultant at SerCon GmbH.

Dr. Stefan Horstmann

VP of PS Core - Patents and Scientific Services
Merck KGaA

Dr. Stefan Horstmann

VP of PS Core - Patents and Scientific Services
Merck KGaA

Dr. Stefan Horstmann is VP of PS Core - Patents and Scientific Services at Merck KGaA.

Dr. Horstmann holds a PhD in Chemistry and is qualified as European and German Patent Attorney. Before becoming a VP of PS Core, he previously served as Head of the Patents B2B Department, and has also served as in-house patent attorney at Merck KGaA and Henkel KGaA and as an IT consultant at SerCon GmbH.

Dr. Horstmann is a member of the European Patent Institute (EPI), the German Chemical Society (GDCh) and the Association of Intellectual Property Experts (VPP). He represents Merck to matters of intellectual property law at the European Chemical Industry Council (CEFIC) and the German Chemical Industry Association (VCI).

 

James Lederer

Chief Scientific Officer
Alloplex Biotherapeutics Inc.

James Lederer

Chief Scientific Officer
Alloplex Biotherapeutics Inc.

James Lederer

Chief Scientific Officer
Alloplex Biotherapeutics Inc.